Flying at My Size: Why Airline Policies Matter
in OAC Blog on November 16, 2025

The holiday season is fast approaching and I just finalized my travel plans. While I’m happy to get to visit loved ones, I’m sad that it will be my last trip with a guaranteed refund for my additional seat.  When Southwest Airlines announced plans to move to assigned seating at the end of 2024, my
Read Article

A Milestone Week for Obesity Care
in OAC Blog on November 13, 2025

By Joe Nadglowski, President and Chief Executive Officer Reflections on a Big Week for Obesity Care The first week of November was quite the whirlwind for the OAC team! We knew it was going to be a busy one, with half of our staff, myself included, in Atlanta for ObesityWeek, The Obesity Society’s annual meeting.
Read Article

This Is What We’re Fighting For: Protect TRICARE Coverage of Obesity Medications
in OAC Blog on November 11, 2025

  Since 2017, TRICARE has provided comprehensive obesity care for its beneficiaries — including coverage for FDA-approved obesity medications. But in August 2025, that changed. TRICARE announced that retirees would no longer have coverage for these medications and that other beneficiaries could only access coverage through in-network providers. This decision isn’t just unfair — it’s dangerous. It
Read Article

Expanding Access to Obesity Medications: How You Helped Make a Difference
in OAC Blog on November 6, 2025

Millions of Americans living with obesity face barriers to accessing the treatment they need, including high out-of-pocket costs and limited coverage under Medicare and Medicaid. Thanks to the advocacy of thousands of supporters like you, today’s announcement marks a meaningful step toward breaking down these long-standing barriers to care. OAC Applauds the Administration The Obesity
Read Article

Obesity Action Coalition (OAC) Applauds the Administration’s Plan to Expand Access to Obesity Medications
in 2025 News Releases on

Tampa, FL — The Obesity Action Coalition (OAC) welcomes today’s announcement from the White House outlining new agreements with pharmaceutical manufacturers to significantly lower the cost of several FDA-approved medications, including those used to treat obesity. Under the new agreements, Medicare beneficiaries will pay a co-pay of just $50 per month, making these life-changing treatments
Read Article

Patients with Obesity Call for Fair Drug Standards: New Research Reveals Strong Demand for FDA and Industry Action on Testing and Labeling
in 2025 News Releases on November 4, 2025

FOR IMMEDIATE RELEASE November 4, 2025 At ObesityWeek 2025, new data show overwhelming public support for ensuring that all medications are evaluated and labeled for safety and efficacy in people with obesity. Atlanta, GA — New research presented today at ObesityWeek 2025, the world’s leading international conference on obesity science and care, shows that people
Read Article